Annexin A5 anticoagulant activity in children with systemic lupus erythematosus and the association with antibodies to domain I of beta 2-glycoprotein I
| Autor: | D M, Wahezi, N T, Ilowite, X X, Wu, L, Pelkmans, B, Laat, L E, Schanberg, J H, Rand, J, Winsor |
|---|---|
| Přispěvatelé: | Promovendi CD, Biochemie, RS: CARIM School for Cardiovascular Diseases |
| Jazyk: | angličtina |
| Rok vydání: | 2013 |
| Předmět: |
Male
Adolescent medicine.drug_class Immunoglobulin G Article pediatric lupus Young Adult Rheumatology Antiphospholipid syndrome immune system diseases medicine Beta 2-Glycoprotein I Humans Lupus Erythematosus Systemic Prospective Studies skin and connective tissue diseases Child beta 2-glycoprotein I Lupus anticoagulant Lupus erythematosus biology business.industry Anticoagulant annexin A5 medicine.disease Lupus Coagulation Inhibitor Immunology Multivariate Analysis biology.protein Antibodies Antiphospholipid Female Antibody Annexin A5 business Follow-Up Studies |
| Zdroj: | Lupus, 22(7), 702-711. SAGE Publications Ltd |
| ISSN: | 0961-2033 |
| DOI: | 10.1177/0961203313490241 |
| Popis: | Children with systemic lupus erythematosus (SLE) have a high prevalence of antiphospholipid (aPL) antibodies and are at increased risk for aPL-related thrombosis. We investigated the association between annexin A5 anticoagulant activity and antibodies to the domain I portion of β2-glycoprotein I (anti-DI antibodies), and propose a potential mechanism for the pathogenesis of aPL-related thrombosis. Using samples from 183 children with SLE collected during the Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE) trial, we examined resistance to the anticoagulant effects of annexin A5, using the annexin A5 resistance (A5R) assay, and evaluated for anti-DI IgG antibodies. Children with SLE had higher frequency of anti-D1 antibodies ( p = 0.014) and significantly reduced A5R compared to pediatric controls: mean A5R = 172 ± 30% versus 242 ± 32% ( p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|